PAR General discussion, page-92

Yeah, I don't mind CEO's becoming Chairman/woman after achieving great results as a CEO. They can continue to give valuable insight to the Board. Its a nice pat on the back for hard work done. PR has under-achieved in the last couple of years.

No-one minds an authorative, well informed figure over-seeing the board when they've shown themselves to be measured and reliable in guiding the business. Paul has not. It reeks of the typical Australian boys club. A nice little semi-retirement with lots of trimmings.

I sold out on Paul's fireside chat and bought back in lower. Sold out again on the recent FDA spike and am back in again around here.

I am only buying back in because I have some confidence in Dr Donna Skerrett, the former chief medical officer. The company needs to forge ahead with regulatory and commercialisation pathways - it would be hard for her, given her experience and Paul's performence, to be more tardy than the company has been already on these fronts.

PAR like so many Aussie bio-techs, great product potential, terrible management performence on bringing it to market. I expect long waits on this stuff, but why do so many Aussie bio-tech promise what are literally B/S timelines?